Publications
Detailed Information
The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Hyunkyung | - |
dc.contributor.author | Bang, Ju-Hee | - |
dc.contributor.author | Nam, Ah-Rong | - |
dc.contributor.author | Park, Ji Eun | - |
dc.contributor.author | Jin, Mei Hua | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.date.accessioned | 2022-04-18T09:24:16Z | - |
dc.date.available | 2022-04-18T09:24:16Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.citation | Cancer Medicine, Vol.9 No.1, pp.43-51 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.other | 108082 | - |
dc.identifier.uri | https://hdl.handle.net/10371/178098 | - |
dc.description.abstract | Objectives Transforming growth factor-beta (TGF-beta) is a multifunctional regulatory factor. Here we measured serum soluble TGF-beta (sTGF-beta) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first-line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF-beta using an enzyme-linked immunosorbent assay. Results The patients' median overall survival (OS) and progression-free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5-12.1) and 6.5 (95% CI, 4.9-8.1) months, respectively. Patients with low sTGF-beta at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF-beta, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF-beta was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF-beta was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). Conclusions Pretreatment sTGF-beta levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF-beta during chemotherapy have prognostic value. | - |
dc.subject | biomarker;chemotherapy;pancreatic cancer;prognosis;transforming growth factor-beta | - |
dc.title | The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy | - |
dc.type | Article; Early Access | - |
dc.contributor.AlternativeAuthor | 오도연 | - |
dc.identifier.doi | 10.1002/cam4.2677 | - |
dc.citation.journaltitle | Cancer Medicine | - |
dc.identifier.scopusid | 2-s2.0-85074937260 | - |
dc.citation.endpage | 51 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 43 | - |
dc.citation.volume | 9 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2677 | - |
dc.identifier.sci | 000495011600001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.